- Home
- ABVX vs RVMD Comparison
ABVX vs RVMD Comparison
Compare ABVX & RVMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABVX
- RVMD
- Stock Information
- Founded
- ABVX 2013
- RVMD 2014
- Country
- ABVX France
- RVMD United States
- Employees
- ABVX N/A
- RVMD N/A
- Industry
- ABVX
- RVMD Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ABVX
- RVMD Health Care
- Exchange
- ABVX Nasdaq
- RVMD Nasdaq
- Market Cap
- ABVX 6.7B
- RVMD 7.5B
- IPO Year
- ABVX N/A
- RVMD 2020
- Fundamental
- Price
- ABVX $90.65
- RVMD $47.59
- Analyst Decision
- ABVX Strong Buy
- RVMD Strong Buy
- Analyst Count
- ABVX 9
- RVMD 15
- Target Price
- ABVX $94.11
- RVMD $74.47
- AVG Volume (30 Days)
- ABVX 957.6K
- RVMD 2.1M
- Earning Date
- ABVX 08-11-2025
- RVMD 11-05-2025
- Dividend Yield
- ABVX N/A
- RVMD N/A
- EPS Growth
- ABVX N/A
- RVMD N/A
- EPS
- ABVX N/A
- RVMD N/A
- Revenue
- ABVX $7,073,400.00
- RVMD N/A
- Revenue This Year
- ABVX $4.44
- RVMD N/A
- Revenue Next Year
- ABVX N/A
- RVMD $454.11
- P/E Ratio
- ABVX N/A
- RVMD N/A
- Revenue Growth
- ABVX N/A
- RVMD N/A
- 52 Week Low
- ABVX $4.77
- RVMD $29.17
- 52 Week High
- ABVX $93.77
- RVMD $62.40
- Technical
- Relative Strength Index (RSI)
- ABVX 74.86
- RVMD 65.52
- Support Level
- ABVX $85.00
- RVMD $45.80
- Resistance Level
- ABVX $90.70
- RVMD $49.50
- Average True Range (ATR)
- ABVX 2.98
- RVMD 1.54
- MACD
- ABVX -0.26
- RVMD 0.05
- Stochastic Oscillator
- ABVX 75.33
- RVMD 74.18
About ABVX Abivax SA American
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.
About RVMD Revolution Medicines Inc.
Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio and SOS1 and 4EBP1/mTORC1 programs.